AI moves deeper into the clinic: three deals this week

Three deals, one direction

Three healthcare announcements landed this week, and they point the same way: this suggests AI is moving out of pilot projects and into the plumbing of clinical work. Johns Hopkins Medicine is co-designing AI-native medical education with OpenEvidence, Commure and Compassus have deployed referral automation across 79 home-care programs, and Zimmer Biomet extended its distribution deal for a handheld surgical robot. All three are company announcements, so treat the numbers as the companies' own — but the pattern of where the money and partnerships are going is the news. m:…7043 m:…4200 m:…6685

The texture of the deals matters. OpenEvidence calls itself the most popular AI for doctors in the United States, and it is free for all verified U.S. clinicians — so the Hopkins partnership is distribution into medical education as much as research. Commure and Compassus spent six months co-designing intake workflows before deploying, which is why the numbers look operational rather than experimental. And the THINK–Zimmer extension follows what the companies describe as a successful initial term — a renewal, not a first date. m:…7043 m:…4200 m:…6685

OpenEvidence and Johns Hopkins: designing the AI-native clinician

OpenEvidence — which describes itself as the most widely adopted medical AI in the United States — and Johns Hopkins Medicine announced a strategic collaboration with two pillars: preparing clinicians for an AI-native environment, and building human-first AI systems that surface and synthesize evidence-based guidelines inside the context of a patient's own history and Hopkins best practices. m:…7043

The framing is deliberate. The collaboration is built on two pillars: training clinicians for AI-native environments, and building AI tools that synthesize evidence-based guidelines in the context of a patient's history. The stated aim is to preserve human-centric clinical judgment while letting AI do the faster, more precise information synthesis. OpenEvidence describes itself as the most popular AI for doctors in the United States — the company's own claim — which explains why Hopkins would pick it as the partner for rebuilding training around reasoning rather than recall. m:…7043

The institutional weight is the story here. Johns Hopkins established the current model of U.S. medical education more than a century ago, and the named leads carry curriculum authority: vice dean for education Sanjay Desai and chief medical informatics and AI officer Sara Murray for Hopkins, chief medical officer Travis Zack for OpenEvidence. That is not a logo swap. The deliverable, as described: human-first AI systems that surface and synthesize the best available evidence inside the context of the patient's own history. m:…7043

Commure and Compassus: referrals in under ten minutes

Commure and Compassus spent six months co-designing intake workflows and built Commure Orchestrator, an AI-native platform that pulls referrals from faxes, payer portals, and email into one interface, triages them, and matches them to clinical capacity. It is now live across 79 Compassus programs in 19 states, supports more than 1,400 team members, and connects to more than 8,500 referring facilities and 2,500 insurance plans. m:…4200

The companies' reported results: referral-to-decision time cut 64%, processing time down from about an hour to under ten minutes, missed referrals down 22% where the system has run longest, and 6% more admissions from faster decisions. About 80% of team members reported high satisfaction in early surveys. These are Compassus and Commure's figures from their own deployment — impressive if they replicate, and the replication question is the whole story for anyone evaluating similar tools. m:…4200

The scale numbers explain why the percentages matter: referrals flowing through a system that pulls from fax, payer portals, and email. At that volume, a 64% cut in referral-to-decision time is not a demo; the implication is thousands of staff-hours saved. Processing time fell from an hour to under ten minutes, missed referrals dropped 22%, and admissions rose 6% — all company-reported figures from the 79-program deployment. And Orchestrator is now offered for enterprise deployment, which makes this announcement a product launch as much as a case study. m:…4200

THINK Surgical and Zimmer Biomet: extending the robot deal

THINK Surgical and Zimmer Biomet extended their limited exclusive distribution and supply agreement for multiple years, following what the companies called a successful initial term. Zimmer Biomet keeps distributing an exclusive version of THINK's wireless, handheld TMINI miniature robotic system, compatible with Zimmer Biomet's Persona Knee System. m:…6685

The extension keeps the wireless, handheld TMINI Miniature System — compatible with Zimmer Biomet's Persona Knee System — in Zimmer's distribution channel under a multi-year agreement. The stated goal is accelerating adoption among orthopedic surgeons. THINK describes its robots as open platforms, a quiet selling point — which suggests an edge where surgeons otherwise lose the choice of implant brand. m:…6685

Zimmer Biomet's framing is ecosystem, not product: the company says it wants the broadest and most flexible set of robotics and enabling technologies, and THINK's open-platform robots — supporting implants from multiple manufacturers rather than locking in one brand — fit that strategy. With operations in more than 25 countries and sales in over 100, Zimmer Biomet is distribution muscle for a privately held robotics maker; the implication is that this buys THINK reach it could not build alone. m:…6685